The ERA Registry Annual Report 2019 : summary and age comparisons

• Published in: Clinical Kidney Journal
• Main Authors: Boenink, Rianne, Astley, Megan E, Huijben, Jilske A, Stel, Vianda S, Kerschbaum, Julia, Ots-Rosenberg, Mai, Åsberg, Anders A, Lopot, Frantisek, Golan, Eliezer, Castro de la Nuez, Pablo, Rodríguez Camblor, Marta, Trujillo-Alemán, Sara, Ruiz San Millan, Juan Carlos, Ucio Mingo, Pablo, Díaz, Juan Manuel, Bouzas-Caamaño, M Encarnación, Artamendi, Marta, Aparicio Madre, Manuel I, Santiuste de Pablos, Carmen, Slon Roblero, María Fernanda, Zurriaga, Oscar, Stendahl, Maria E, Bell, Samira, Idrizi, Alma, Ioannou, Kyriakos, Debska-Slizien, Alicja, Galvão, Ana A, De Meester, Johan M, Resić, Halima, Hommel, Kristine, Radunovic, Danilo, Pálsson, Runólfur, Lassalle, Mathilde, Finne, Patrik, De Los Ángeles-Garcia Bazaga, María, Gjorgjievski, Nikola, Seyahi, Nurhan, Bonthuis, Marjolein, Ortiz, Alberto, Jager, Kitty J, Kramer, Anneke
• Other Authors: Other departments, Faculty of Medicine, Office of Division of Clinical Services I
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2022
• Subjects: Nýrnalæknisfræði; Nýrnalækningar; dialysis; epidemiology; kidney transplantation; graft survival; patient survival; ESRD; Nephrology; Transplantation; Baxter; Iceland
• Online Access: https://hdl.handle.net/20.500.11815/3137; https://doi.org/10.1093/ckj/sfab273

Funding Information: The ERA Registry is funded by the ERA. This article was written by R. Boenink et al. on behalf of the ERA Registry, which is an official body of the ERA. In addition, S.B. reports personal fees from AstraZeneca, outside the submitted work; A.D.-S. reports personal fees from Astellas and Fresenius, outside the submittedwork; F.L. reports personal fees fromMeditesPharma, outside the submitted work; R.P. reports grants from The Iceland Centre for Research, Landspitali University Hospital Research Fund and University of Iceland Research Fund, outside the submitted work; P.F. reports grants fromFinska läkaresällskapet and Liv och Hälsa, outside the submittedwork; M.F.S.R. reports personal fees from Baxter and Fresenius, outside the submitted work; A.O. reports grants from Sanofi, and personal fees from Astellas, AstraZeneca, Amicus, Bayes, Fresenius Medical Care and Idorsia, outside the submitted work; and K.J.J. reports grants from ERA, during the conduct of the study. Publisher Copyright: © 2021 The Author(s). BACKGROUND: Data on renal replacement therapy (RRT) for end-stage renal disease were collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons. METHODS: Individual patient data for 2019 were provided by 35 registries and aggregated data by 17 registries. Using these data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated. RESULTS: In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥65 years of age and 21% had diabetes mellitus as primary renal disease (PRD), and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had ...